Prasanthi Geda
Overview
Explore the profile of Prasanthi Geda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baumgartner C, Ebrahimi-Nik H, Iracheta-Vellve A, Hamel K, Olander K, Davis T, et al.
Nature
. 2023 Oct;
622(7984):850-862.
PMID: 37794185
Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance. The protein tyrosine phosphatases PTPN2...
2.
Reutershan M, Machacek M, Altman M, Bogen S, Cai M, Cammarano C, et al.
J Med Chem
. 2021 Oct;
64(21):16213-16241.
PMID: 34714078
Identification of low-dose, low-molecular-weight, drug-like inhibitors of protein-protein interactions (PPIs) is a challenging area of research. Despite the challenges, the therapeutic potential of PPI inhibition has driven significant efforts toward...
3.
Hopkins B, Zhang H, Bharathan I, Li D, Pu Q, Zhou H, et al.
ACS Med Chem Lett
. 2021 Sep;
12(9):1435-1440.
PMID: 34531952
Herein the discovery of potent IDO1 inhibitors with low predicted human dose is discussed. Metabolite identification (MetID) and structural data were used to strategically incorporate cyclopropane rings into this tetrahydronaphthyridine...
4.
Yu W, Deng Y, Hopkins B, Huang X, Sloman D, Zhang H, et al.
Bioorg Med Chem Lett
. 2021 Jun;
47:128214.
PMID: 34166782
A novel series of IDO1 inhibitors have been identified with good IDO1 Hela cell and human whole blood activity. These inhibitors contain an indoline or a 3-azaindoline scaffold. Their structure-activity-relationship...
5.
Li D, Deng Y, Achab A, Bharathan I, Hopkins B, Yu W, et al.
ACS Med Chem Lett
. 2021 Mar;
12(3):389-396.
PMID: 33738066
Indoleamine-2,3-dioxygenase-1 (IDO1) has emerged as an attractive target for cancer immunotherapy. An automated ligand identification system screen afforded the tetrahydroquinoline class of novel IDO1 inhibitors. Potency and pharmacokinetic (PK) were...
6.
Pu Q, Zhang H, Guo L, Cheng M, Doty A, Ferguson H, et al.
ACS Med Chem Lett
. 2020 Aug;
11(8):1548-1554.
PMID: 32832022
Indoleamine-2,3-dioxygenase 1 (IDO1) inhibition and its combination with immune checkpoint inhibitors like have drawn considerable attention from both academia and the pharmaceutical industry. Here, we describe the discovery of a...
7.
White C, McGowan M, Zhou H, Sciammetta N, Fradera X, Lim J, et al.
ACS Med Chem Lett
. 2020 Apr;
11(4):550-557.
PMID: 32292563
Indoleamine-2,3-dioxygenase-1 (IDO1) has emerged as a target of significant interest to the field of cancer immunotherapy, as the upregulation of IDO1 in certain cancers has been linked to host immune...
8.
McLeod R, Gil M, Chen D, Cabal A, Katz J, Methot J, et al.
J Pharmacol Exp Ther
. 2019 Feb;
369(2):223-233.
PMID: 30804001
We leveraged a clinical pharmacokinetic (PK)/pharmacodynamics (PD)/efficacy relationship established with an oral phosphatidylinositol 3-kinase (PI3K) inhibitor (Idelalisib) in a nasal allergen challenge study to determine whether a comparable PK/PD/efficacy relationship...
9.
Brandish P, Palmieri A, Antonenko S, Beaumont M, Benso L, Cancilla M, et al.
Bioconjug Chem
. 2018 Jun;
29(7):2357-2369.
PMID: 29923706
Glucocorticoids (GCs) are excellent anti-inflammatory drugs but are dose-limited by on-target toxicity. We sought to solve this problem by delivering GCs to immune cells with antibody-drug conjugates (ADCs) using antibodies...
10.
Kern J, Cancilla M, Dooney D, Kwasnjuk K, Zhang R, Beaumont M, et al.
J Am Chem Soc
. 2016 Jan;
138(4):1430-45.
PMID: 26745435
As part of an effort to examine the utility of antibody-drug conjugates (ADCs) beyond oncology indications, a novel pyrophosphate ester linker was discovered to enable the targeted delivery of glucocorticoids....